Safety of MK0928 on Insomnia in the Elderly (0928-005)(COMPLETED)

Phase 3CompletedNCT00095043

H. Lundbeck A/S320 enrolled

Overview

The purpose of this trial is to study the safety of MK0928 on insomnia in the elderly.

The duration of treatment is 1 year.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

320

Sex: ALLMin age: 65 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Diagnosis of Insomnia

Safety and tolerability after 12 months of treatment

Discontinuation symptoms and rebound insomnia using sleep diary and Tyrer Withdrawal Symptom Questionnaire

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.